Induced Pluripotent Stem Cells (iPSC) are originated from skin or blood cells. iPSCs are cells that are reprogrammed from somatic cells using different transcription factors. These cells are pluripotent, have the potential for self-renewal, and can differentiate into any of the 220+ human cell types. iPSC has certain advantages over other stem cell types in regenerative medicine and wound healing models. iPSCs are used to produce patient-specific cells, which can be transplanted to the site of injury or tissue degeneration due to various disease conditions. iPS cells have the potential to become embryos if exposed to suitable conditions. Some important characteristics of iPSC are abundant somatic cells of the donor that can be used. Issues of histocompatibility with donor/recipient transplants can be avoided. Very useful for drug development and developmental studies.
Market growth factors are increasing research on personalized or precise medicine and extended applications in regenerative treatments and therapies due to the high therapeutic potential of iPS cells. Uprising trials and research on diseases like Parkinson's disease, Anemia, and cardiac syndromes will contribute to iPSC production. In the manufacturing of iPS cells, the use of an automated platform will boost the market with cost reduction and increased output. In Apr 2022, Ncardia launched a new business, Cellistic™, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on cell therapy development and manufacturing. Affordable cost for cell therapy and demonstration of these therapies' safety and efficacy are market restraining factors. Also, methods for ensuring reproducibility and maintenance, as differentiated tissues are uncertain, are expected to hamper the market growth. The standard technique to create iPS cells uses viruses to transfer the reprogramming genes into the skin cells, which is one of iPS cells' cons.
Tumorigenicity, immune rejection, phenotypic heterogeneity of therapeutic cell products and genetic instability are prime challenges in stem cell research that will impact the production of iPS Cells.
iPSCs manufacturing services market is segmented into two main fragments. The first segmentation is by application, including Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, and Emerging Applications. The last segmentation is by end-user, which comprises Pharmaceutical & Biotechnology Companies, Academic institutes, Research Laboratories & CROs, Hospitals & Surgical Centres, Cell & Tissue Banks, Other End Users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, & the Middle East and Africa.
North America is likely to witness rapid growth in the forecast period, followed by Europe due to fast research on cardiac diseases, neuropathies and personalized medicine production. Also, significant funding for development in iPSC manufacturing will be responsible for the growth.
Significant market key players are I Peace Inc., Lonza Group AG, Axol Bioscience Ltd., FUJIFILM Cellular Dynamics, Inc., Pluristyx, Inc., Ncardia, Cynata Therapeutics Limited, Evotec SE, Celogics Inc, Catalent, Inc, CCRM, Applied StemCell Inc. (ASC), RoslinCT, Takara Bio Inc, Thermo Fisher Scientific, Inc, Other Prominent Players